# A Study Of Stellate Ganglion Blockade With Liposomal Bupivacaine In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery

Study · id `cardio:ct-nct07570940` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07570940](<https://clinicaltrials.gov/study/NCT07570940>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07570940

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 450 participants.

## Technical summary

Registry record NCT07570940. Randomized; double masking; primary purpose treatment. Start 2026-09-14 (anticipated); primary completion 2030-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 450 participants (planned count; ClinicalTrials.gov record NCT07570940, source copy `cardio:ctgov-nct07570940-2026-09-09`, retrieved 2026-10-26)
- Planned start: 2026-09-14 (anticipated) (ClinicalTrials.gov record NCT07570940, source copy `cardio:ctgov-nct07570940-2026-09-09`, retrieved 2026-10-26)
- Primary completion: 2030-09 (anticipated) (ClinicalTrials.gov record NCT07570940, source copy `cardio:ctgov-nct07570940-2026-09-09`, retrieved 2026-10-26)
- Completion: 2030-09 (anticipated) (ClinicalTrials.gov record NCT07570940, source copy `cardio:ctgov-nct07570940-2026-09-09`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07570940, source copy `cardio:ctgov-nct07570940-2026-09-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07570940-2026-09-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study Of Stellate Ganglion Blockade With Liposomal Bupivacaine In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery
- Condition: Coronary Artery Disease
- Condition: Atrial Fibrillation
- Intervention (Drug): Liposomal bupivacaine
- Intervention (Drug): Placebo
- Lead sponsor: Mayo Clinic
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Mayo Clinic (`cardio:org-mayo-clinic`)

## Provenance

Content hash: 8d881211e9267de9fd096088b234aa80234dc34e6b45199336023fa94830ae92
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
